Apoprotein C-III Deficiency Markedly Stimulates Triglyceride Secretion in Vivo: Comparison with Apoprotein E
Overview
Physiology
Affiliations
Apoprotein (apo) C-III plays an important role in the development of hypertriglyceridemia by inhibiting triglyceride (TG) removal. However, the effect of apo C-III on TG production remains unclear. We measured TG secretion rate (TGSR) in apo C-III gene-disrupted (apo C-III-null) mice to investigate the influence of this protein on TG turnover. TGSR measured by the Triton WR-1339 method was increased twofold in these mice compared with wild-type (WT) mice. Obesity was induced by the injection of gold-thioglucose (GTG), which made the WT mice hypertriglyceridemic due to a threefold increase of TGSR. However, GTG-induced obesity failed to increase TG in apo C-III-null mice, although TGSR was increased 10-fold, suggesting substantial stimulation of TG removal. Apo E-null mice were severely hypercholesterolemic but were not hypertriglyceridemic, and TGSR was rather decreased. GTG-induced obesity made these mice hypertriglyceridemic because of TG overproduction to an extent similar to that seen in WT mice. These results suggest that apo C-III deficiency potently enhances TG turnover, especially when TG production is stimulated, and that apo E deficiency is not always rate limiting for TG production.
Oluranti O, Agboola E, Fubara N, Ajayi M, Michael O Ann Med. 2021; 53(1):1108-1117.
PMID: 34259114 PMC: 8280890. DOI: 10.1080/07853890.2021.1947519.
Jana L, Maity P, Perveen H, Dash M, Jana S, Dey A Environ Sci Pollut Res Int. 2018; 25(36):36462-36473.
PMID: 30374712 DOI: 10.1007/s11356-018-3542-5.
Pathophysiology of Diabetic Dyslipidemia.
Hirano T J Atheroscler Thromb. 2018; 25(9):771-782.
PMID: 29998913 PMC: 6143775. DOI: 10.5551/jat.RV17023.
Fernandes G, Bocco B, Fonseca T, McAninch E, Jo S, Lartey L Cell Rep. 2018; 22(2):523-534.
PMID: 29320745 PMC: 6474669. DOI: 10.1016/j.celrep.2017.12.053.
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis.
Guo Y, Garcia-Barrio M, Wang L, Chen Y Cardiovasc Drugs Ther. 2016; 30(1):1-11.
PMID: 26847647 PMC: 7088260. DOI: 10.1007/s10557-016-6644-7.